The combination of semaglutide and cagrilintide represents a more advanced approach to fat loss by targeting multiple hormonal pathways involved in appetite, satiety, and glucose regulation. Rather Clinical trials of subcutaneous tirzepatide, retatrutide, and Download Scientific Diagram Tirzepatide Dosage Chart & Dosing Guide for Weight Loss Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current GLP 1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect